GPP
TCRX icon

Great Point Partners’s TScan Therapeutics TCRX Stock Holding History

Great Point Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,016,375
Closed -$5.06M – 32
2024
Q3 		$5.06M Buy
1,016,375
+75,544
+8% +$456K 1.49% 25
2024
Q2 		$5.5M Buy
+940,831
New +$7.41M 1.05% 26

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Great Point Partners's TCRX Position: Q4 2024 in Review

Great Point Partners sold out of TScan Therapeutics (TCRX) in Q4 2024, closing a stake of 1,016,375 shares — an estimated $5.06M sold.

Great Point Partners first reported a position in TCRX in Q2 2024 and held it in 2 quarters. The position peaked at $5.5M in Q2 2024. 89 funds tracked by Wall St. Rank hold TCRX as of Q4 2024.

  • Great Point Partners reported no remaining TScan Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Great Point Partners sold 1,016,375 TScan Therapeutics shares in Q4 2024, an estimated $5.06M.
  • Great Point Partners first reported a position in TScan Therapeutics in Q2 2024 and held it in 2 quarters.
  • Great Point Partners's TScan Therapeutics position peaked at $5.5M in Q2 2024.
  • 89 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2024.

Based on Great Point Partners's 13F filing for Q4 2024, filed 14 Feb 2025.